SynthesisFrontiers in pharmacology2026
Quercetin-associated cardioprotection in preclinical myocardial ischemia-reperfusion injury: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Prompt reperfusion is the standard treatment for acute myocardial infarction, but it can induce myocardial ischemia-reperfusion injury (MIRI). Quercetin, a plant-derived flavonoid, has been investigated as a potential cardioprotective agent in preclinical MIRI models; however, its effect magnitude, dose-exposure relevance, and mechanistic specificity remain uncertain. This systematic review and meta-analysis evaluated quercetin monotherapy in vivo and Methods: Databases were searched from inception to March 2026 for controlled preclinical studies comparing quercetin monotherapy with vehicle-treated MIRI controls. The primary endpoint was myocardial infarct size. Secondary outcomes included myocardial injury biomarkers, hemodynamic recovery, oxidative-stress markers, and inflammatory cytokines. Random-effects models calculated standardized mean differences (SMDs) or mean differences (MDs). Subgroup, leave-one-out, split-control, risk-of-bias-informed, dose-response meta-regression, and publication-bias analyses were performed where feasible. This review was registered in the International Prospective Register of Systematic Reviews (PROSPERO; CRD420261325366). Results: Twenty studies were included. Quercetin was associated with reduced infarct size compared with vehicle controls (SMD = -2.98, 95% confidence interval -4.37 to -1.58; P < 0.00001). A split-control sensitivity analysis showed an attenuated but directionally consistent effect (SMD = -2.22, 95% confidence interval -3.16 to -1.28). Exploratory dose-response meta-regression did not identify a clear linear association between systemic dose and infarct-size effect. Quercetin was associated with an 18.35-percentage-point improvement in left ventricular developed pressure (LVDP) recovery and favorable changes in selected maximal rates of pressure change (±dP/dtmax). It was also associated with reduced myocardial injury biomarkers, decreased malondialdehyde (MDA), increased superoxide dismutase (SOD) and glutathione (GSH), and lower tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Exploratory subgroup analyses suggested attenuated responsiveness in comorbid or metabolically altered models, but this finding was limited and confounded. Egger testing suggested possible small-study effects for infarct size. Conclusion: Quercetin is associated with a directionally consistent preclinical cardioprotective signal in rodent Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261325366, identifier CRD420261325366.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.